Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring-guided dosing of risperidone or aripiprazole in children and adolescents with autism spectrum disorder
NL-OMON60605Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone and aripiprazole in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in BMI z-score at 6 months. Started Jul 2024; status: recruiting.
02
Drugs
risperidonearipiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON60605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60605.